TCGA-CQ-5327-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.520
- ALLOGRAFT_REJECTION+0.480
- MYC_TARGETS_V1+0.420
- MYC_TARGETS_V2+0.420
- OXIDATIVE_PHOSPHORYLATION+0.390
- INFLAMMATORY_RESPONSE+0.320
- COMPLEMENT+0.300
- DNA_REPAIR+0.290
- IL6_JAK_STAT3_SIGNALING+0.280
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ANGIOGENESIS-0.300
- PANCREAS_BETA_CELLS-0.270
- HYPOXIA-0.220
- HEDGEHOG_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.180
- UV_RESPONSE_DN-0.160
- TGF_BETA_SIGNALING-0.140
- ANDROGEN_RESPONSE-0.110
- PROTEIN_SECRETION-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-F7-A620-01A-11R-A28V-07 | — | — | 0.857 |
| 2 | SRR35579807 | — | C | 0.848 |
| 3 | TCGA-E7-A7XN-01A-11R-A352-07 | — | — | 0.831 |
| 4 | ERR2208905 | — | — | 0.828 |
| 5 | TCGA-UF-A7JO-01A-11R-A34R-07 | — | — | 0.825 |
| 6 | c63f3f74-14fa-4a9e-9925-30b0f5da7dd9 | — | — | 0.822 |
| 7 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.806 |
| 8 | BS_M7HCF7DW | high-grade glioma | — | 0.799 |
| 9 | TCGA-73-4666-01A-01R-1206-07 | — | cohortA1 | 0.798 |
| 10 | TCGA-BH-A0C0-01A-21R-A056-07 | — | C | 0.795 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.520 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.480 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.420 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.320 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.220 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.180 | Idelalisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| MYOGENESIS | 0.150 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |